ORIC Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

ORIC PharmaceuticalsDer Gewinn des Unternehmens wird voraussichtlich um 6.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 69.6% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -49.6% betragen.

Wichtige Informationen

-6.9%

Wachstumsrate der Gewinne

4.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	69.6%
Zukünftige Eigenkapitalrendite	-49.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Aug 21

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Jan 18

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Sep 27

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Jan 24

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Oct 14

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Oct 08

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

Aug 11

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 24

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Mar 08

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Nov 23

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Aug 05

ORIC Pharmaceuticals EPS beats by $0.04

May 06

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Apr 16

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Jan 01

Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101

Dec 21

Oric Pharma prices stock offering at $23

Nov 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ORIC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	11	-185	-150	-164	9
12/31/2025	N/A	-161	-123	-127	11
12/31/2024	N/A	-127	-97	-89	11
9/30/2024	N/A	-120	-110	-109	N/A
6/30/2024	N/A	-111	-100	-100	N/A
3/31/2024	N/A	-102	-96	-95	N/A
12/31/2023	N/A	-101	-87	-86	N/A
9/30/2023	N/A	-93	-78	-77	N/A
6/30/2023	N/A	-93	-78	-76	N/A
3/31/2023	N/A	-90	-75	-73	N/A
12/31/2022	N/A	-89	-77	-75	N/A
9/30/2022	N/A	-91	-78	-76	N/A
6/30/2022	N/A	-85	-71	-69	N/A
3/31/2022	N/A	-85	-69	-67	N/A
12/31/2021	N/A	-79	-60	-60	N/A
9/30/2021	N/A	-84	-62	-61	N/A
6/30/2021	N/A	-91	-59	-59	N/A
3/31/2021	N/A	-81	-53	-52	N/A
12/31/2020	N/A	-74	-46	-45	N/A
9/30/2020	N/A	-54	-35	-35	N/A
6/30/2020	N/A	-35	-31	-30	N/A
3/31/2020	N/A	-30	-27	-26	N/A
12/31/2019	N/A	-27	-24	-24	N/A
12/31/2018	N/A	-21	-21	-21	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ORIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ORIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ORIC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ORIC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ORIC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ORIC wird voraussichtlich in 3 Jahren unrentabel sein.

ORIC Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 9.3% to US$19.13

Price target increased by 7.7% to US$17.50

Price target increased by 12% to US$15.14

Price target decreased to US$14.00

Price target decreased to US$14.00

Price target decreased to US$28.00

Recent updates

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

New minor risk - Share price stability

ORIC Pharmaceuticals, Inc. Appoints Keith Lui as Senior Vice President of Commercial and Medical Affairs

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

Independent Director exercised options to buy US$181k worth of stock.

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Price target increased by 9.3% to US$19.13

ORIC Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

President notifies of intention to sell stock

Price target increased by 7.7% to US$17.50

President notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944

President exercised options and sold US$125k worth of stock

ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Price target increased by 12% to US$15.14

President notifies of intention to sell stock

President notifies of intention to sell stock

ORIC Pharmaceuticals, Inc. announced that it has received $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals, Inc. announced that it expects to receive $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) dropped from Russell 2000 Dynamic Index

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

President recently bought US$1.3m worth of stock

Price target decreased to US$14.00

Price target decreased to US$14.00

Price target decreased to US$28.00

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

ORIC Pharmaceuticals, Inc. Provides Corporate Update and Highlights Key Upcoming Milestones

ORIC Pharmaceuticals, Inc. Presents Data Supporting the Therapeutic Potential of ORIC3 in Multiple Myeloma At the American Society of Hematology (ASH) Annual Meeting

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Price target decreased to US$33.00

ORIC Pharmaceuticals, Inc. Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

President notifies of intention to sell stock

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals, Inc. Announces Initial Data from an Ongoing Phase 1B Study Evaluating Oric-10

Independent Director & Member of Scientific Advisory Board Richard Scheller has left the company

ORIC Pharmaceuticals, Inc. Reports Initial Clinical Data Being Presented at ASCO from Phase 1B Trial of ORIC-101 in Combination with Nab-Paclitaxel

ORIC Pharmaceuticals EPS beats by $0.04

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

President notifies of intention to sell stock

New 90-day low: US$28.36

ORIC Pharmaceuticals, Inc. Provides Corporate Update

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101

New 90-day high: US$36.60

New 90-day high: US$26.00

Oric Pharma prices stock offering at $23

ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc

New 90-day low: US$19.75